HR tech remains incredibly attractive to investors. A lot of the investment in HR tech in June so far has focused itself on the recruitment space.
For instance, in the past week, Goodtime nabbed $9.4 million for its AI-based hiring solution, Syndio received $1 million in capital to support its pay equity technology, while Oyster and Boundless are both attracting investment to support their hiring from anywhere products.
But Vancouver-based people analytics platform Visier has now bucked that trend and raised $125 million in a Series E round.
The investment round was led by Goldman Sachs Asset Management. Existing investors – Sorenson Capital, Foundation Capital, Summit Partners, and Adams Street Partners – also participated.
This Series E brings Visier’s total funding to $219.5 million and brings its value to more than $1 billion, therefore transforming the company into a unicorn. Visier claims to be the first unicorn in the people analytics space.
This comes on the back of an unprecedented year of growth for Visier as companies have increasingly relied on data and insights to deal with, and make the right decisions about, the shift to remote working.
It has now exceeded 8,000 customers – notable examples are Merck KGaA, Uber and Adobe. It has also processed more than 12 million employee recorders in 75 countries, as well as embedded partnerships with other vendors, including Cegid and Degreed.
Visier CEO Ryan Wong commented: “There is unprecedented demand for companies to better understand the people within their organizations.
“From HR leaders to people managers and executives, having insight into a workforce is critical for delivering the right outcomes for the business, the employee, the customer, and a fair and just society.”
Goldman Sachs Asset Management managing director Holger Staude added: “Access to information about employees and the health of an organization has never been more critical.
“We’re excited to partner with Visier at this pivotal moment and support the company’s continued growth.”
Allie started her career as a business journalist writing about innovation in the pharma and medtech industries. She learned how crucial technology was to these medical breakthroughs and therefore became keen to further explore how it could also disrupt not just our health, and the way we live, but the way we work. Allie’s work has been featured in Pharma Tech Focus, Medical Technology Magazine, Verdict.co.uk, and Glass Magazine.